Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
6.17
-0.15 (-2.37%)
At close: Mar 27, 2026, 4:00 PM EDT
6.60
+0.43 (6.97%)
After-hours: Mar 27, 2026, 7:52 PM EDT
Valneva SE Revenue
In the year 2025, Valneva SE had annual revenue of 174.66M EUR with 3.00% growth. Valneva SE had revenue of 47.69M in the quarter ending December 31, 2025, a decrease of -9.92%.
Revenue (ttm)
174.66M EUR
Revenue Growth
+3.00%
P/S Ratio
2.70
Revenue / Employee
259,136 EUR
Employees
674
Market Cap
552.89M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 174.66M | 5.08M | 3.00% |
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | 7.74M | 7.35% |
| Dec 31, 2017 | 105.29M | 7.40M | 7.56% |
| Dec 31, 2016 | 97.89M | 14.56M | 17.47% |
| Dec 31, 2015 | 83.33M | 40.91M | 96.41% |
| Dec 31, 2014 | 42.43M | 6.44M | 17.89% |
| Dec 31, 2013 | 35.99M | 326.00K | 0.91% |
| Dec 31, 2012 | 35.67M | 2.78M | 8.46% |
| Dec 31, 2011 | 32.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| CorMedix | 311.71M |
| Zevra Therapeutics | 106.47M |
| 4D Molecular Therapeutics | 85.21M |
| Prothena Corporation | 9.68M |
| Upstream Bio | 2.85M |
| YD Bio | 510.36K |
VALN News
- 2 days ago - Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC - GlobeNewsWire
- 3 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 4 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - GlobeNewsWire
- 5 days ago - Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges - GuruFocus
- 5 days ago - An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive - WSJ
- 5 days ago - Lyme disease vaccine 70 percent effective: Pfizer - The Hill
- 6 days ago - Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial - Euronews
- 6 days ago - Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive - Benzinga